Cyclin A is a reliable proliferation marker in endometrial cancer cell lines

Horie,Kayo; Yamamoto,Hayate; Karube,Kouhei; Takebayashi,Kai; Yoshino,Hironori; Yoshioka,Haruhiko; Watanabe,Jun

doi:10.3892/ol.2019.10135

Cyclin A is a reliable proliferation marker in endometrial cancer cell lines

Authors:
- Kayo Horie
- Hayate Yamamoto
- Kouhei Karube
- Kai Takebayashi
- Hironori Yoshino
- Haruhiko Yoshioka
- Jun Watanabe
View Affiliations

Affiliations: Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan, Department of Medical Technology, Hirosaki University School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
Published online on: March 8, 2019 https://doi.org/10.3892/ol.2019.10135
Pages: 4455-4462
Copyright: © Horie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin A, a cell cycle regulatory protein, promotes cell proliferation and has been observed to be highly expressed in cancer and to promote tumor growth; however, its value as a marker for endometrial carcinoma has not yet been established. Accordingly, the aim of the present study was to clarify whether cyclin A can be used as a cell proliferation marker using the endometrial carcinoma cell lines Ishikawa and HEC‑50B, derived from patients with low‑grade and high‑grade cancer, respectively. The expression of cyclin A was determined by flow cytometry using double staining with FITC and 7‑AAD, and immunocytochemical staining. The results were compared to those of Ki‑67, the widely used cell proliferation marker that is considered to be a prognostic marker in endometrial cancer. The flow cytometry results revealed that cyclin A expression was significantly higher in HEC‑50B than in Ishikawa cells during the logarithmic growth phase. In addition, cyclin A expression was consistently higher than Ki‑67 expression in the examined cell lines. Immunocytochemical staining confirmed cyclin A expression in HEC‑50B and Ishikawa cells, demonstrating significantly higher expression during the logarithmic growth phase than during the stationary phase. By contrast, Ki‑67 was expressed in almost 90% of the cells, irrespective of their growth state. These results indicate that cyclin A expression is significantly increased in cells with higher proliferative ability and is specifically expressed in cells that have passed the G1‑S checkpoint. Therefore, cyclin A may be a reliable proliferation biomarker for endometrioid carcinoma.

View Figures

View References

1	Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D and Katabuchi H: Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol. 28:e322017. View Article : Google Scholar : PubMed/NCBI
2	Tran AQ and Gehrig P: Recent advances in endometrial cancer. F1000Res. 6:812017. View Article : Google Scholar : PubMed/NCBI
3	Żyła MM, Wilczyński JR, Kostrzewa M, Księżakowska-Łakoma K, Nowak M, Stachowiak G, Szyłło K and Stetkiewicz T: The significance of markers in the diagnosis of endometrial cancer. Prz Menopauzalny. 15:176–185. 2016.PubMed/NCBI
4	Salvesen HB, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol. 17:1382–1390. 1999. View Article : Google Scholar : PubMed/NCBI
5	Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
6	Schwarting R, Gerdes J, Niehus J, Jaeschke L and Stein H: Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods. 90:65–70. 1986. View Article : Google Scholar : PubMed/NCBI
7	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
8	Kosmas K, Stamoulas M, Marouga A, Kavantzas N, Patsouris E and Athanassiadou P: Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma. Diagn Cytopathol. 41:212–217. 2013. View Article : Google Scholar : PubMed/NCBI
9	Masjeed NMA, Khandeparkar SGS, Joshi AR, Kulkarni MM and Pandya N: Immunohistochemical study of ER, PR, Ki67 and p53 in endometrial hyperplasias and endometrial carcinomas. J Clin Diagn Res. 11:EC31–EC34. 2017.PubMed/NCBI
10	Yang B, Shan B, Xue X, Wang H, Shan W, Ning C, Zhou Q, Chen X and Luo X: Predicting lymph node metastasis in endometrial cancer using serum CA125 combined with immunohistochemical markers PR and Ki67, and a comparison with other prediction models. PLoS One. 11:e01551452016. View Article : Google Scholar : PubMed/NCBI
11	Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse T, et al: Ki-67 in endometrial cancer: Scoring optimization and prognostic relevance for window studies. Mod Pathol. 30:459–468. 2017. View Article : Google Scholar : PubMed/NCBI
12	Watanabe J, Kamata Y, Seo N, Okayasu I and Kuramoto H: Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J Steroid Biochem Mol Biol. 107:163–171. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T and Kuramoto H: Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 128:307–312. 2002. View Article : Google Scholar : PubMed/NCBI
14	Watanabe J, Nishimura Y, Tsunoda S, Kawaguchi M, Okayasu I and Kuramoto H: Liquid-based preparation for endometrial cytology-usefulness for predicting the prognosis of endometrial carcinoma preoperatively. Cancer. 117:254–263. 2009.PubMed/NCBI
15	Kato N, Watanabe J, Jobo T, Nishimura Y, Fujisawa T, Kamata Y and Kuramoto H: Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol. 129:222–226. 2003.PubMed/NCBI
16	Nishimura Y, Watanabe J, Jobo T, Kato N, Fujisawa T, Kamata Y and Kuramoto H: Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Res. 24:2185–2191. 2004.PubMed/NCBI
17	Sobczak-Thepot J, Harper F, Florentin Y, Zindy F, Brechot C and Puvion E: Localization of cyclin A at the sites of cellular DNA replication. Exp Cell Res. 206:43–48. 1993. View Article : Google Scholar : PubMed/NCBI
18	Desdouets C, Sobczak-Thépot J, Murphy M and Bréchot C: Cyclin A: Function and expression during cell proliferation. Prog Cell Cycle Res. 1:115–123. 1995. View Article : Google Scholar : PubMed/NCBI
19	Santala S, Talvensaari-Mattila A, Soini Y, Honkavuori-Toivola M and Santala M: High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma. Tumour Biol. 35:5395–5399. 2014. View Article : Google Scholar : PubMed/NCBI
20	Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T and Konishi I: Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: Positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 34:471–478. 2003. View Article : Google Scholar : PubMed/NCBI
21	Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326. 2002. View Article : Google Scholar : PubMed/NCBI
22	Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H, Watanabe S, et al: Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
23	Husdal A, Bukholm G and Bukholm IR: The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell Oncol. 28:107–116. 2006.PubMed/NCBI
24	Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C and Ristimäki A: Prognostic significance of cyclin A in gastric cancer. Int J Cancer. 119:1897–1901. 2006. View Article : Google Scholar : PubMed/NCBI
25	Paterlini P, Suberville AM, Zindy F, Melle J, Sonnier M, Marie JP, Dreyfus F and Bréchot C: Cyclin A expression in human hematological malignancies: A new marker of cell proliferation. Cancer Res. 53:235–238. 1993.PubMed/NCBI
26	Nishida M, Kasahara K, Kaneko M, Iwasaki H and Hayashi K: Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nihon Sanka Fujinka Gakkai Zasshi. 37:1103–1111. 1985.(In Japanese). PubMed/NCBI
27	Nishida M, Kasahara K, Oki A, Satoh T, Arai Y and Kubo T: Establishment of eighteen clones of Ishikawa cells. Hum Cell. 9:109–116. 1996.PubMed/NCBI
28	Kuramoto H, Hamamo M, Nishida M, Toguchi A, Jobo T, Suzuki M and Osanai K: Establishment of a cell line of human endometrial carcinoma originated from ascitic fluid. Acta Obstet Gynaecol Jpn. 28:1405–1406. 1976.
29	Nordström B, Strang P, Bergström R, Nilsson S and Tribukait B: A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer. 78:1942–1951. 1996. View Article : Google Scholar : PubMed/NCBI